Previous Close | 1.9300 |
Open | 1.9000 |
Bid | 1.9200 x 1200 |
Ask | 2.0200 x 1400 |
Day's Range | 1.9000 - 2.0250 |
52 Week Range | 1.5000 - 4.5790 |
Volume | |
Avg. Volume | 364,603 |
Market Cap | 46.315M |
Beta (5Y Monthly) | 0.82 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9800 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.15 |
LOS ANGELES, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bel
Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct to Stage II Surgery in HLHS - Enrollment ongoing in Phase 2 ELPIS II trial - MIAMI, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syn
Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Call Transcript November 10, 2023 Longeveron Inc. misses on earnings expectations. Reported EPS is $-0.28 EPS, expectations were $-0.24. Operator: Greetings, and welcome to the Longeveron’s Third Quarter 2023 Earnings call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal […]